Radioactive 'Smart Bomb' for tumours tested in early trial

NCT ID NCT03746431

Terminated Disease control Sponsor: Fusion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a safe dose and check for side effects, but it was terminated before completion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radioactive antibody (225Ac-FPI-1434) targeting IGF-1R
What this could lead to: If successful, this could point toward a new treatment option for patients with advanced solid tumours that have not responded to standard therapies.
What could go wrong: This was an early phase 1 trial, so safety and dosing were still being figured out. The trial was terminated, meaning it did not continue as planned, and results may not be available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma breast cancer breast neoplasm cervical cancer endometrial cancer endometrium neoplasm head and neck squamous cell carcinoma Her2-receptor negative breast cancer neoplasm ovarian cancer Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma Uterine Cervical Neoplasms uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENOCORTICAL CARCINOMA ADVANCED SOLID TUMOURS BREAST CANCER CERVICAL CANCER ENDOMETRIAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) HER2-NEGATIVE BREAST CANCER OVARIAN CANCER TRIPLE-NEGATIVE BREAST CANCER (TNBC) UVEAL MELANOMA

Contacts and locations

Locations

Austin Hospital

Heidelberg, Victoria, 3084, Australia
Centre Hospitalier De I'Universite de Montreal

Montreal, Quebec, H2X 0C1, Canada
City of Hope

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Juravinski Cancer Center - Hamilton Health

Hamilton, Ontario, L8V 5C2, Canada
Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, 55455, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2C1, Canada
Quebec University Hospital- Laval

Québec, Quebec, G1R 2J6, Canada
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.